Evidence map›Paper›PMID 40474999›Full record

ArticleEClinicalMedicine2025

Impact of HIV infection on the dynamics of liver stiffness in patients with hepatitis C virus chronic infection after sustained virological response.

Jésica Martín-Carmona, Anaïs Corma-Gómez, Jose M Moyano, Francisco Téllez, Dolores Arenga-Barrios, Miriam Serrano-Fuentes, Aitana Carla Morano Vázquez, Diana Corona-Mata, Miguel Nicolás Navarrete Lorite, Francisco Jesús Vera-Méndez and 13 more

Registry-linked trialAbstract read
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04460157 (Development of a Predictive Model of Liver Complications Emergence in Patients With Advanced Fibrosis Who Achieve Sustained Virological Response With Direct-acting Antivirals-based Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04460157 unknown statusnot on this map

Development of a Predictive Model of Liver Complications Emergence in Patients With Advanced Fibrosis Who Achieve Sustained Virological Response With Direct-acting Antivirals-based Therapy

Typeobservational_patient_registrySponsorHospital Universitario de ValmeRan2011 to 2021Enrolled1,035ConditionsHepatitis C, Chronic, Sustained Virological Response, Direct-acting Antivirals, Hepatocellular Carcinoma
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Jésica Martín-CarmonaClinical Virology and STIs Group, Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Sevilla, Spain.
Anaïs Corma-GómezClinical Virology and STIs Group, Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Sevilla, Spain.
Jose M MoyanoDepartment of Computer Science and Artificial Intelligence, Universidad de Sevilla, Spain.
Francisco TéllezUnit of Infectious Diseases, Hospital Universitario de Puerto Real, Cádiz, Spain.
Dolores Arenga-BarriosUnit of Infectious Diseases, Hospital Universitario de Puerto Real, Cádiz, Spain.
Miriam Serrano-FuentesUnit of Infectious Diseases, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain.
Aitana Carla Morano VázquezUnit of Infectious Diseases, Hospital Universitario Alvaro Cunqueiro, Vigo, Spain.
Diana Corona-MataCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Miguel Nicolás Navarrete LoriteUnit of Infectious Diseases, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Francisco Jesús Vera-MéndezSection of Infectious Medicine/Service of Internal Medicine, Hospital General Universitario Santa Lucía, Cartagena, Spain.
Isabel BarrosoUnit of Clinical Microbiology, University Hospital Jerez, Cadiz, Spain.
Rosario PalaciosUnit of Infectious Diseases and Microbiology, Hospital Virgen de la Victoria, Málaga, Spain.
Ignacio de Los SantosCentro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Olga BelinchónUnit of Internal Medicine, Hospital General Virgen de la Luz, Cuenca, Spain.
Carlos GaleraHospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Arkaitz ImazHIV and STI Unit, Department of Infectious Diseases, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain.
Dolores MerinoUnit of Infectious Diseases and Microbiology, Hospital Universitario Juan Ramón Jimenez, Huelva, Spain.
Sergio Javier Reus-BañulsHospital General Universitario de Alicante, Alicante, Spain.
Maria Jose GalindoInternal Medicine, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Miguel Ángel López-ZuñigaInfectious Disease Unit, Internal Medicine Service, Virgen de las Nieves University Hospital, Granada, Spain.
Juan A PinedaClinical Virology and STIs Group, Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Sevilla, Spain.
Juan MacíasClinical Virology and STIs Group, Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Sevilla, Spain.
GEHEP-011 Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: After sustained virological response (SVR), liver stiffness (LS) usually decreases. However, information related to the impact of HIV co-infection in patients with advanced fibrosis is scarce. The aim was to analyze the impact of HIV co-infection on the LS dynamics after HCV cure. Methods: Prospective study conducted in the GEHEP-011 multicenter cohort (initiated in October 2011-November 2023, ID NCT04460157), including patients with chronic HCV infection, with or without HIV co-infection, fulfilling: 1) SVR with direct-acting antivirals; 2) pre-treatment LS ≥ 9.5 kPa; 3) available measurement of LS at SVR. Pre-treatment, SVR and annual post-treatment LS were assessed. The primary outcome was time to LS normalization achievement (≤7.2 kPa) in two consecutive examinations. Findings: 1138 patients were included, 678 (60%) of whom were living with HIV (PLWH). The median time between the first to the last measure was 35 (17-69) months. In total, 390 [34% (95% confidence interval, 31%-37%)] patients achieved LS normalization, 169 [37% (CI 95%, 34%-43%)] individuals with HCV mono-infection vs. 221 [32% (CI 95%, 29%-36%)] PLWH achieved LS normalization (p = 0.003). The propensity score (PS) for HIV infection was calculated. In a multivariate model for competing risks (death was the competing event) adjusted for HIV, PS and diabetes, HIV infection was associated with a lower probability of achieving normalization [sHR = 0.82 (95% CI, 0.67-1.00), p = 0.045]. Matching by closer PS was performed. In the resultant subset, the probability of achieving LS normalization was again lower in PLWH [sHR = 0.76 (0.56-0.97), p < 0.001]. Interpretation: After SVR, the probability of reaching LS normalization is significantly lower in PLWH. This could have implications on the development of long-term clinical events. Funding: Project PI19/01443, ERDF/ESF "Investing in your future", GLD21_00096, GEHEP-011 project, B-0061-2021, JR24/00044, A1-0060-2021, CM23/00255, CM22/00176.

Indexed as

Hepatitis CHIVLiver stiffnessSustained viral responseTransient elastography

Identifiers

PMID40474999
PMCPMC12140061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.